Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?

Front Immunol. 2020 Jun 18:11:1459. doi: 10.3389/fimmu.2020.01459. eCollection 2020.

Authors

Martina Severa¹, Cinthia Farina², Marco Salvetti^{3

4}, Eliana Marina Coccia¹

Affiliations

¹ Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
² Institute of Experimental Neurology (INSpe), Division of Neuroscience, IRCSS San Raffaele Scientific Institute, Milan, Italy.
³ Center for Experimental Neurological Therapies, Sant'Andrea Hospital, Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University, Rome, Italy.
⁴ Istituto Neurologico Mediterraneo (INM) Neuromed, Pozzilli, Italy.

No abstract available

Keywords: SARS-CoV-2; antiviral-activity; immunoregulation; multiple scleorsis (MS); type I IFN.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antiviral Agents / therapeutic use*
Betacoronavirus / drug effects
Betacoronavirus / physiology*
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections / drug therapy*
Coronavirus Infections / virology
Drug Repositioning / methods*
Humans
Immunologic Factors / therapeutic use*
Interferon-beta / therapeutic use*
Multiple Sclerosis / drug therapy*
Pandemics
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / virology
SARS-CoV-2
Virus Replication / drug effects

Substances

Antiviral Agents
Immunologic Factors
Interferon-beta